Cornell University
Veterinary Specialists

Canine Clinical Trial

Low Volume Lyophilized Early Trauma Resuscitation (LoVLETR)

Hemorrhagic shock is a major cause of death in veterinary patients, particularly in cases of trauma. Based on mortality data from military and civilian studies, revised fluid resuscitation guidelines emphasize the use of platelets and plasma while minimizing crystalloid IV fluid resuscitation to significantly increase rates of survival following trauma and intraabdominal hemorrhage.

GOALS: This study involves the administration of two novel lyophilized blood products, StablePlate RX® (lyophilized canine platelets) and StablePlas® (lyophilized canine plasma) – to evaluate their effects on hemodynamic stabilization in hemorrhagic shock and to determine survival benefit when compared to current veterinary standards of care. This study is funded by the Department of Defense It is a collaborative effort between researchers and clinicians at Iowa State University, Auburn University, and several other institutions, including CUVS.

ELIGIBILITY: A dog is deemed eligible to be enrolled in the study if s/he weighs 5 – 60 kg, and is determined to be in hemorrhagic shock due to documented trauma or secondary to internal bleeding not related to a bleeding disorder or anaphylaxis. The eligibility of the specific patient will be determined by the Critical Care team.

COMPENSATION: In addition to a direct financial incentive for participating, the study will cover the costs of serial bloodwork performed (complete blood count, chemistry profile, blood gas analysis, and coagulation testing) – over a $2,000 value. The costs of any blood products deemed necessary during the patient's hospitalization and stabilization will also be covered by the study.

CUVS PRINCIPAL INVESTIGATOR: Bridget M. Lyons, VMD, DACVECC

Interested in participating?

For questions or more information on the study, contact our research coordinator at research@cuvs.org or 203.595.2777.